Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
← catalyst calendarNCT07116967 · readout in 1,610 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
3,040estimated
Sites
394
Countries
Argentina, Australia, Belgium +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-22 | actual | When the study began enrolling |
| Primary completion | 2031-01-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-16 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Plaque Psoriasis
Interventions
- Drug: Deucravacitinib — also filed as SOTYKTU
- Drug: Ustekinumab
Primary outcome
what the primary-completion date above is the date OFComposite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization
measured Up to 5 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed